Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $8.3 million.

  • Tg Therapeutics' Non-Current Deffered Revenue fell 4836.08% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 4836.08%. This contributed to the annual value of $12.1 million for FY2024, which is 10088.1% up from last year.
  • As of Q3 2025, Tg Therapeutics' Non-Current Deffered Revenue stood at $8.3 million, which was down 4836.08% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Non-Current Deffered Revenue ranged from a high of $16.2 million in Q3 2024 and a low of $190000.0 during Q3 2023
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $533000.0 (2021), whereas its average is $3.3 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 840842.11% in 2024, then crashed by 5546.35% in 2025.
  • Quarter analysis of 5 years shows Tg Therapeutics' Non-Current Deffered Revenue stood at $457000.0 in 2021, then plummeted by 33.26% to $305000.0 in 2022, then surged by 1872.46% to $6.0 million in 2023, then surged by 100.88% to $12.1 million in 2024, then tumbled by 30.92% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $1.7 million for Q2 2025, and $6.6 million during Q1 2025.